Long-term follow up of REDO study of ultra-low dose RTX (200mg vs 500mg vs 1000mg every 6 months) in RA. All doses appeared similarly effective, but also had similar adverse events. Potentially cost and time saving. Abstr#1443 #ACR21 @RheumNow https://t.co/0FRYPUOMpY